[ad_1]
At around 9 a.m. on Wednesday morning, the FDA communicated the detailed case of Pfizer to the agency and its external advisers to authorize the booster doses of Covid-19. Three hours later, the FDA released its own analysis.
For most documents, it is as if the agency and the company are having two different conversations.
The documents are a prelude to an advisory committee hearing that will debate whether the agency should approve the booster injections. The question turned out to be deeply polarizing. President Biden has vowed to allow the boosters on the database from Israel and elsewhere, angering some public health officials inside and outside the FDA who fear the president interfere with the agency’s independence and argue that existing data does not support such shots, especially when much of the world remains unvaccinated.
Keep Reading Endpoints With A Free Membership
Unlock this story instantly and join over 117,400 biopharmacy professionals reading Endpoints daily, and it’s free.
[ad_2]
Source link